November 15th, 2026Five Under 5: Top Oncology Videos for the Week of 11/8The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.Read more
November 13th, 2026FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBCThe FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.Read more
November 12th, 2026FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate CancerPhase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.Read more
November 10th, 2026Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate CancerExperts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.Read more
November 8th, 2026JNJ-87189401 Plus Pasritamig Drives Deep PSA Responses With Favorable Safety in Pretreated mCRPCA dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.Read more
November 7th, 2026VET3-TGI Generates Responses in Checkpoint Inhibitor–Refractory Cutaneous CancersVET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.Read more
November 6th, 2026Canakinumab Reduces Nodule Size in High-Risk Lung PrecancersIL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.Read more
November 6th, 2026VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILsVGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.Read more